Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18292615 | 0.85 | TDP1 (0.57) | PTK2L3MBTL1TDP1RAB9ATSHR | |
| SCHEMBL14496793 | 0.83 | PTK2 (0.49) | PTK2L3MBTL1TDP1TRPA1RAB9A | |
| SCHEMBL851343 | 0.83 | DEGS1 (0.56) | — | |
| SCHEMBL1126145 | 0.83 | RAB9A (0.62) | RAB9ASMN1; SMN2TP53NFKB1NFKB2 | |
| SCHEMBL6609814 | 0.83 | NAMPT (0.52) | RAB9ASMN1; SMN2TP53NPC1ALDH1A1 | |
| SCHEMBL24608579 | 0.82 | RAB9A (0.48) | PTK2L3MBTL1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL28717918 | 0.82 | PTK2 (0.48) | PTK2L3MBTL1TDP1TRPA1RAB9A | |
| SCHEMBL29750530 | 0.82 | RAB9A (0.48) | PTK2L3MBTL1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL12461458 | 0.81 | GSK3B (0.44) | PTK2L3MBTL1RAB9AMAPK1MAPT | |
| SCHEMBL56219 | 0.81 | PTGS1 (0.50) | RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650358-B2 | Pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2970200-A1 | PYRIDINE CDK9 KINASE INHIBITORS | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105189481-A | Pyridine cdk9 kinase inhibitors | ABBVIE INC | 2015-12-23 | — | — | CN | disclosed |
| EP-1507756-B1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9035096-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2014160017-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8569543-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7282502-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7238717-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1507756-A4 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK6 | PTK2 599/4885L3MBTL1 2739/4885TDP1 1335/4885 |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | PTK2 690/4885L3MBTL1 3577/4885TDP1 3267/4885 |
| US-20140107160-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | PTK2 690/4885L3MBTL1 3577/4885TDP1 3267/4885 |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | PTK2 690/4885L3MBTL1 3577/4885TDP1 3267/4885 |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | PTK2 690/4885L3MBTL1 3577/4885TDP1 3267/4885 |
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | PTK2 690/4885L3MBTL1 3577/4885TDP1 3267/4885 |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | PTK2 690/4885L3MBTL1 3577/4885TDP1 3267/4885 |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | PTK2 690/4885L3MBTL1 3577/4885TDP1 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.